Effects of safinamide on pain in patients with fluctuating Parkinson's disease

Non-motor symptoms (NMS) are integral to Parkinson's Disease (PD) and management remains a challenge. Safinamide is a novel molecule in relation to addressing NMS due to its multifocal mechanism of action with both dopaminergic and non-dopaminergic properties.To investigate the efficacy of safinamide on NMS and its burden in PD patients with motor fluctuations after 6 months of treatment.This observational, multicenter, open-label, pilot study...